FindTrial
Sign In

Evaluation of the effectiveness of calcium hydroxide-based medications in root canal inflammation

Monitoring of the Periapical Inflammatory Process before and after the use of different intracanal medications through the levels of pro-inflammatory cytokines, metalloproteinases and their antagonists

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-9xhgs6
Enrollment
Unknown
Registered
2020-08-18
Start date
2014-08-15
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Pulp Necrosis

Interventions

Group 1 Number of participants: 10 Procedures performed: Endodontic treatment Medication: Calcium hydroxide with serum Availability: 1:1 Medication time: 14 days Method of administration: intracanal p
Drug
E06.397.778
E06.397.778.889
C07.320.830.700
D01.045.250.313

Sponsors

Universidade Estadual Paulista Júlio de Mesquita Filho - Campus São José dos Campos
Lead Sponsor
Universidade Estadual Paulista Júlio de Mesquita Filho - Campus São José dos Campos
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients in adulthood; Need for endodontic treatment; Permanent teeth with primary endodontic infection; Unirradicular; Presence of a single canal and periapical lesion; Absence of periodontal pockets greater than 4 mm; No mobility.

Exclusion criteria

Exclusion criteria: Teeth that can not be insulated with the rubber dam; With root fracture; Exposure of the pulp chamber; Patients who have used antibiotics or antifungals in the last 3 months; Patients with systemic disease.

Design outcomes

Primary

MeasureTime frame
Expected outcome 1-Reduction of matrix metalloproteinases (MMP-1, MMP-2, MMP-9) with resolution or significant reduction of the periapical inflammatory process, verified by means of the Immunoenzymatic Assay (ELISA) method, which allows the detection of amounts of protein nanograms (10-9 g) from the observation of a variation of at least 5% in the pre- and post-intervention measurements.—

Secondary

MeasureTime frame
Expected outcome 1-Increased release of tissue inhibitors of matrix metalloproteinase metalloproteinases (TIMP-1, TIMP-2) with resolution or significant reduction of the periapical inflammatory process, verified through the immunoenzymatic assay method (ELISA), which allows the detection of quantities of protein of the order of nanograms (10-9 g) from the observation of a variation of at least 5% in the pre and post-intervention measurements.—

Countries

Brazil

Contacts

Public ContactBruna Jordão Motta Corazza

Universidade Estadual Paulista Júlio de Mesquita Filho - Campus São José dos Campos

brunajordao1991@gmail.com+55-012-991512822

Outcome results

None listed

Source: REBEC (via WHO ICTRP)